The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report

The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report

Background. Lung cancer (LC) occupies a leading position among malignant tumors in the world, it accounts for 11.4% of the total malignant neoplasms. In 2020, there were 2 206 771 new cases of LC and 1 796 144 deaths worldwide. Among the histological variants, small cell LC (SCLC) has the most unfav...

Full description

Bibliographic Details
Main Authors:	Nikolai A. Ognerubov, Tatyana S. Antipova
Format:	Article
Language:	Russian
Published:	IP Habib O.N. 2021-08-01
Series:	Современная онкология
Subjects:	small cell lung cancer pd-1/pd-l1 checkpoint inhibitors atezolizumab combined positron emission and x-ray computed tomography
Online Access:	https://modernonco.orscience.ru/1815-1434/article/viewFile/72330/pdf

Similar Items

Experience of using atezolizumab in 1st line therapy of metastatic urothelial cancer
by: R. A. Gafanov, et al.
Published: (2019-10-01)

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
by: Facchinetti F, et al.
Published: (2018-09-01)

A Case of Pseudoprogression During Atezolizumab Therapy  in Lung Adenocarcinoma
by: Xue WANG, et al.
Published: (2019-06-01)

A Patient with Atezolizumab-Induced Autoimmune Diabetes Mellitus Presenting with Diabetic Ketoacidosis
by: Sharen Lee, et al.
Published: (2021-09-01)

Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report
by: Yoshitaka Yamaguchi, et al.
Published: (2020-07-01)

Atezolizumab-Induced Autoimmune Diabetes in a Patient With Metastatic Lung Cancer
by: Jin Sothornwit, et al.
Published: (2019-06-01)

A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab
by: Jiamao Lin, et al.
Published: (2021-06-01)

A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma
by: Cheong E Von, et al.
Published: (2021-01-01)

An exceptional response to immunotherapy with chemotherapy in metastatic lung cancer
by: Xenia Elena BACINSCHI, et al.
Published: (2020-06-01)

Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy
by: M. Xipell, et al.
Published: (2018-07-01)

Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab
by: Luciana Molinero, et al.
Published: (2019-10-01)

Review of checkpoint immunotherapy for the management of non-small cell lung cancer
by: Raju S, et al.
Published: (2018-07-01)

Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC
by: I. А. Dzhanyan, et al.
Published: (2021-06-01)

Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis
by: Dan-Ni Li, et al.
Published: (2021-06-01)

Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors
by: Shifaa M. Abdin, et al.
Published: (2018-01-01)

Real‐world efficacy of atezolizumab in non‐small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti‐PD‐1 antibody
by: Naoki Furuya, et al.
Published: (2021-03-01)

Atezolizumab-induced bilateral anterior uveitis: A case report
by: Tsuyoshi Mito, et al.
Published: (2021-12-01)

Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition
by: Lei Zhang, et al.
Published: (2019-04-01)

Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells
by: Nishant Mohan, et al.
Published: (2019-09-01)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
by: Yaxiong Zhang, et al.
Published: (2018-12-01)

Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance
by: Yulei Wang, et al.
Published: (2021-08-01)

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
by: Sarabjot Pabla, et al.
Published: (2019-02-01)

Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer
by: Aydin AM, et al.
Published: (2017-03-01)

Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors
by: Zhiyang Li, et al.
Published: (2021-03-01)

Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
by: François Ghiringhelli, et al.
Published: (2019-08-01)

Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
by: Passiglia F, et al.
Published: (2021-02-01)

Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
by: Shuai Wang, et al.
Published: (2018-08-01)

Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
by: Gang Liu, et al.
Published: (2021-08-01)

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
by: Seetharamu N, et al.
Published: (2017-07-01)

Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)
by: Caicun ZHOU, et al.
Published: (2020-02-01)

ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
by: J. A. Kyte, et al.
Published: (2020-06-01)

Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for  Non-small Cell Lung Cancer
by: Sixuan WU, et al.
Published: (2019-07-01)

MODERN POSSIBILITIES OF THERAPY WITH INHIBITORS OF CONTROL POINTS IN METASTATIC UROTHELIAL CANCER
by: R. A. Gafanov, et al.
Published: (2018-03-01)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
by: Inokuchi J, et al.
Published: (2019-05-01)

Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
by: Yating Zhao, et al.
Published: (2021-07-01)

Biomarkers for immunotherapy in bladder cancer: a moving target
by: David H. Aggen, et al.
Published: (2017-11-01)

Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
by: Ranjan Pathak, et al.
Published: (2020-12-01)

Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody
by: Kohei Fujita, et al.
Published: (2020-01-01)

Serum sCD25 Protein as a Predictor of Lack of Long-Term Benefits from Immunotherapy in Non-Small Cell Lung Cancer: A Pilot Study
by: Anna Siemiątkowska, et al.
Published: (2021-07-01)

Immunotherapy protocols in lung cancer
by: Nandini Menon, et al.
Published: (2018-01-01)

Cannot write session to /tmp/vufind_sessions/sess_nu216jdd0gnpi8aon401u2o4re